RPG Life Sciences Q3 FY26: revenue up 4%, 9M PAT rises 29%
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.3 pts less than Nifty Microcap 250 and 7.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
RPG Life Sciences reported Q3 FY26 standalone revenue of Rs 180 cr, up 4% YoY. Q3 profit after tax dropped 37% YoY to Rs 22.1 cr due to Rs 8.4 cr in exceptional charges. Nine-month revenue grew 4% to Rs 531 cr while PAT rose 29% to Rs 85.3 cr. Exceptional items include fire incident net loss and Rs 11 cr charge for new labour codes. Board approved transfer of API division to a new wholly owned subsidiary.
Q3 PAT fell sharply on one-offs but 9M PAT up 29 percent shows underlying strength. API division restructuring may streamline operations. Watch insurance recovery.